NCT00219154已完成3 期
A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 1,125
- 试验地点
- 2
- 主要终点
- Change from baseline in diastolic blood pressure after 26 weeks
研究概览
简要总结
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with essential hypertension
排除标准
- •Severe hypertension
- •History or evidence of a secondary form of hypertension
- •History of myocardial infarction. Other protocol-defined inclusion exclusion criteria also apply
结局指标
主要结局
Change from baseline in diastolic blood pressure after 26 weeks
次要结局
- Change from baseline systolic blood pressure after 26 weeks
- Mean sitting diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 26 weeks
- Achieve blood pressure of < 140/90 mmHg after 26 weeks
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of AmlodipineHypertensionNCT00294710Novartis976
已完成
3 期
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)Myocardial InfarctionNCT00414609Novartis820
已完成
3 期
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe HypertensionHypertensionNCT00219050Novartis180
已完成
4 期
Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection FractionHeart FailureNCT00982033Wake Forest University Health Sciences52
已完成
4 期
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.Essential HypertensionNCT00654875Novartis328